PCIA
GRCE

Prime Capital Investment Advisors’s Grace Therapeutics GRCE Stock Holding History

Prime Capital Investment Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-42
Closed -$1K – 563
2021
Q1 		$1K Hold
42
– – ﹤0.01% 456
2020
Q4 		$1K Buy
+42
New +$485 ﹤0.01% 448

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prime Capital Investment Advisors's GRCE Position: Q2 2021 in Review

Prime Capital Investment Advisors sold out of Grace Therapeutics (GRCE) in Q2 2021, closing a stake of 42 shares — an estimated $1K sold.

Prime Capital Investment Advisors first reported a position in GRCE in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q1 2021. 26 funds tracked by Wall St. Rank hold GRCE as of Q2 2021.

  • Prime Capital Investment Advisors reported no remaining Grace Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 42 Grace Therapeutics shares in Q2 2021, an estimated $1K.
  • Prime Capital Investment Advisors first reported a position in Grace Therapeutics in Q4 2020 and held it in 2 quarters.
  • Prime Capital Investment Advisors's Grace Therapeutics position peaked at $1K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2021.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.